The present embodiments relate to elite event NS-B50027-4, seeds and oils obtained from NS-B50027-4, progeny derived from NS-B50027-4, the genetic and phenotypic characteristics of NS-B50027-4, and compositions and methods for the identification of elite event NS-B50027-4. In particular, NS-B50027-4 is a transgenic canola line capable of producing at least 5% DHA in its seed oil.

Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.

The present invention relates to the technical field of chemical drugs and crystal form processes, and to a pyrroloquinoline quinine B crystal form and a preparation method therefor. The present invention comprehensively characterizes the pyrroloquinoline quinine B crystal form by virtue of means such as X-ray powder diffraction analysis, thermo-gravimetric analysis, and differential scanning calorimetry analysis so as to find the fact that the pyrroloquinoline quinine B crystal form is high in crystallinity and low in hygroscopicity, and a regular crystal form can be formed, thereby facilitating process treatment and improvement of physical and chemical properties of a medicine, and improving the patent medicine performance. The preparation method for the pyrroloquinoline quinone B crystal form provided in the present invention is simple, easy to control, and high in reproducibility.

Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.

Microencapsulation of -alanine uses -alanine as a core material and a mixture of a wall material and an additive as a release material. The additive comprises: a fatty acid-based saturated or unsaturated fatty acid glyceride containing 12-22 carbon atoms and a phospholipid. The fatty acid glyceride is a mono-fatty acid glyceride or a di-fatty acid glyceride, or a mixture formed by mixing the mono-fatty acid glyceride and the di-fatty acid glyceride at arbitrary proportions. The microencapsulation technique solves problems occurring with the use of -alanine as a raw material, such as high moisture absorption tendency thereof, unpleasant smell and stinging accompanying administration of the same. The invention selects and combines the wall material and the additive to attain a balance between embedment and release with respect to a microencapsulated -alanine product, and effectively optimizes release kinetics of the product, thereby enabling a stable release of the product, and realizing effective embedment and uniform release. Therefore, the microencapsulated -alanine is applicable to the preparation of food, drugs, health-enhancing products and functional food.